PA
PETX

Perceptive Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Perceptive Advisors’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-256,500
Closed -$1.62M – 225
2016
Q2 		$1.62M Sell
256,500
-35,300
-12% -$227K 0.11% 91
2016
Q1 		$1.61M Buy
+291,800
New +$1.1M 0.14% 90

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perceptive Advisors's PETX Position: Q3 2016 in Review

Perceptive Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 256,500 shares — an estimated $1.62M sold.

Perceptive Advisors first reported a position in PETX in Q1 2016 and held it in 2 quarters. The position peaked at $1.62M in Q2 2016. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

  • Perceptive Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Perceptive Advisors sold 256,500 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $1.62M.
  • Perceptive Advisors first reported a position in Aratana Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • Perceptive Advisors's Aratana Therapeutics, Inc. position peaked at $1.62M in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Perceptive Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.